Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo

Journal of Immunology

Volumn 178, Issue 3, 2007, Pages 1564-1572

  Sanchez, Phillip J ^a   McWilliams, Jennifer A ^a   Haluszczak, Catherine ^a   Yagita, Hideo ^b   Kedl, Ross M ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD70 ANTIGEN; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; IMMUNIZATION; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 33846540410     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.3.1564     Document Type: Article

References (57)

1. Baylor, N. W., W. Egan, and P. Richman. 2002. Aluminum salts in vaccines: US perspective. Vaccine 20: S18-S23.
2. Audibert, F. 2003. Adjuvants for vaccines, a quest. Int. Immunopharmacol. 3: 1187-1193.
3. Hadden, J. W. 1994. T-cell adjuvants. Int. J. Immunopharmacol 16: 703-710.
4. Pulendran, B. 2004. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199: 227-250.
5. Akira, S. 2003. Mammalian Toll-like receptors. Curr. Opin. Immunol. 15: 238.
6. - dendritic cells. J. Immunol. 171: 1156-1163.
7. + T cell responses and protection against leishmania major infection. J. Exp. Med. 195: 1565-1573.
8. + T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199: 775-784.
9. + T cell responses. J. Immunol. 174: 7676-7683.
10. Lore, K., M. R. Betts, J. M. Brenchley, J. Kuruppu, S. Khojasteh, S. Perfetto, M. Roederer, R. A. Seder, and R. A. Koup. 2003. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol 171: 4320-4328.
11. Tritel, M., A. M. Stoddard, B. J. Flynn, P. A. Darrah, C. Y. Wu, U. Wille, J. A. Shah, Y. Huang, L. Xu, M. R. Betts, et al. 2003. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J. Immunol. 171: 2538-2547.
12. Busch, D. H., and E. G. Pamer. 1999. T lymphocyte dynamics during Listeria monocytogenes infection, Immunol. Lett. 65: 93-98.
13. Busch, D. H., and E. G. Pamer. 1999. T cell affinity maturation by selective expansion during infection. J. Exp. Med. 189: 701-710.
14. + T cell response during acute LCMV infection. Adv. Exp. Med. Biol. 452: 111-122.
15. + T cells during an acute virus. Infect. Immun. 8: 167-175.
16. + T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201: 95-104.
17. Hendriks, J., L. A. Gravestein, K. Tesselaar, R. A. van Lier, T. N. Schumacher, and J. Borst. 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol 1: 433-440.
18. + T cell formation. J. Exp. Med. 199: 1595-1605.
19. Arens, R., K. Tesselaar, P. A. Baars, G. M. van Schijndel, J. Hendriks, S. T. Pals, P. Krimpenfort, J. Borst, M. H. van Oers, and R. A. van Lier. 2001. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFN-γ-mediated B cell depletion. Immunity 15: 801-812.
20. + T cells. J. Immunol. 174: 710-717.
21. Cormary, C., R. Gonzalez, J. C. Faye, G. Favre, and A. F. Tilkin-Mariame. 2004. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Ther. 11: 497-507.
22. Couderc, B., L. Zitvogel, V. Douin-Echinard, L. Djennane, H. Tahara, G. Favre, M. T. Lotze, and P. D. Robbins. 1998. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 5: 163-175.
23. Douin-Echinard, V., P. D. Robbins, M. T. Lotze, G. Favre, and B. Couderc. 1998. Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70. Adv. Exp. Med. Biol. 451: 353-357.
24. Florido, M., M. Borges, H. Yagita, and R. Appelberg. 2004. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium. J. Leukocyte Biol. 76: 1039-1046.
25. Lorenz, M. G., J. A. Kantor, J. Schlom, and J. W. Hodge. 1999. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum. Gene Ther. 10: 1095-1103.
26. + cytotoxic T cell responses in vivo. J. Immunol. 172: 6039-6046.
27. Taraban, V. Y., T. F. Rowley, and A. Al-Shamkhani. 2004. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J. Immunol. 173: 6542-6546.
28. Tesselaar, K., L. A. Gravestein, G. M. van Schijndel, J. Borst, and R. A. van Lier. 1997. Characterization of murine CD70, the ligand of the TNF receptor family member CD27. J. Immunol. 159: 4959-4965.
29. + T cell-mediated alloimmune responses in vivo. J. Immunol. 174: 1357-1364.
30. Tesselaar, K., Y. Xiao, R. Arens, G. M. van Schijndel, D. H. Schuurhuis, R. E. Mebius, J. Borst, and R. A. van Lier. 2003. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J. Immunol. 170: 33-40.
31. Iwamoto, S., M. Ishida, K. Takahashi, K. Takeda, and A. Miyazaki. 2005. Lipopolysaccharide stimulation converts vigorously washed dendritic cells (DCs) to nonexhausted DCs expressing CD70 and evoking long-lasting type 1 T cell responses. J. Leukocyte Biol. 78: 383-392.
32. + antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. Nat. Immunol 6: 698-706.
33. + T cell priming. J. Immunol. 177: 2969-2975.
34. Adam, O., A. Vercellone, F. Paul, P. F. Monsan, and G. Puzo. 1995. A nondegradative route for the removal of endotoxin from exopolysaccharides. Anal. Biochem. 225: 321-327.
35. Kedl, R. M., W. A. Rees, D. A. Hildeman, B. Schaefer, T. Mitchell, J. Kappler, and P. Marrack. 2000. T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med. 192: 1105-1114.
36. Gibson, S. J., L. M. Imbertson, T. L. Wagner, T. L. Testertnan, M. J. Reiter, R. L. Miller, and M. A. Tomai. 1995. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J. Interferon Cytokine Res. 15: 537-545.
37. Gomez-Gomez, L., G. Felix, and T. Boller. 1999. A single locus determines sensitivity to bacterial flagellin in Arabidopsis thaliana. Plant J. 18: 277-284.
38. Felix, G., J. D. Duran, S. Volko, and T. Boller. 1999. Plants have a sensitive perception system for the most conserved domain of bacterial flagellin. Plant J. 18: 265-276.
39. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6: 769-776.
40. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291: 2413-2417.
41. Reinhardt, R. L., A. Khoruts, R. Merica, T. Zell, and M. K. Jenkins. 2001. Visualizing the generation of memory CD4 T cells in the whole body. Nature 410: 101-105.
42. Watts, T. H. 2005. Tnf/Tnfr family members in costimulation of T cell responses. Annu. Rev. Immunol. 23: 23-68.
43. Lens, S. M., K. Tesselaar, M. H. van Oers, and R. A. van Lier. 1998. Control of lymphocyte function through CD27-CD70 interactions. Semin. Immunol. 10: 491-499.
44. Arens, R., M. A. Nolte, K. Tesselaar, B. Heemskerk, K. A. Reedquist, R. A. van Lier, and M. H. van Oers. 2004. Signaling through CD70 regulates B cell activation and IgG production. J. Immunol. 173: 3901-3908.
45. + cytotoxic T lymphocytes in HIV-infected patients. J. Exp. Med. 200: 1407-1417.
46. - dendritic cells. J. Immunol. 171: 1156-1163.
47. Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116-126.
48. Erickson, L. D., B. G. Durell, L. A. Vogel, B. P. O'Connor, M. Cascalho, T. Yasui, H. Kikutani, and R. J. Noelle. 2002. Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J. Clin. Invest. 109: 613-620.
49. + T cells in the absence of tumor-antigen vaccination. Proc. Natl. Acad. Sci. USA 98: 10811-10816.
50. Mauri, C., L. T. Mars, and M. Londei. 2000. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat. Med. 6: 673-679.
51. Vonderheide, R. H., J. P. Dutcher, J. E. Anderson, S. G. Eckhardt, K. F. Stephans, B. Razvillas, S. Garl, M. D. Butine, V. P. Perry, R. J. Armitage, et al. 2001. Phase 1 study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19: 3280-3287.
52. Akira, S., and S. Sato. 2003. Toll-like receptors and their signaling mechanisms. Scand. J. Infect. Dis. 35: 555-562.
53. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
54. + T-helper and a T-killer cell. Nature 393: 474-478.
55. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
56. + T cell response. J. Immunol. 161: 674-683.
57. Byrne, J. A., J. L. Butler, and M. D. Cooper. 1988. Differential activation requirements for virgin and memory T cells. J. Immunol. 141: 3249-3257.